Risk of Having a First Neurologic Event is Decreased with Increased Sun Exposure and Higher Blood Le - National Multiple Sclerosis Society

Skip to navigation Skip to content

News

Share

Risk of Having a First Neurologic Event is Decreased with Increased Sun Exposure and Higher Blood Levels of Vitamin D, Society-Supported Australian Study Suggests

February 8, 2011

Findings in line with others suggesting these factors may lower the risk for MS

Higher levels of sun exposure and higher blood levels of vitamin D were both associated with decreased risk of having a first demyelinating event that can be the first indicator of multiple sclerosis, in a comprehensive study undertaken in Australia, called the Ausimmune Study. (A first demyelinating event, in this study called FDE, is also known as clinically isolated syndrome (CIS), a first neurologic episode caused by inflammation/demyelination in the brain or spinal cord.) Some of these individuals developed MS during the study and others did not, however findings were similar in either case. Robyn Lucas, PhD, Anthony McMichael, PhD (The Australian National University, Canberra) and colleagues across Australia report their findings in Neurology (2011;76:540-548). This study was supported by the National MS Society, the National Health and Medical Research Council of Australia, the ANZ William Buckland Foundation, and MS Research Australia.

The findings provide additional support for previous suggestions that sun exposure and vitamin D may help protect against developing MS. It remains to be seen whether safe and effective strategies can be developed that utilize this potential protection without the risks involved in overexposure to the sun or overdoses of vitamin D supplements, and whether these findings have relevance for individuals who already have MS.

Background: In all parts of the world, MS is more common at latitudes that are farther from the equator and less common in areas closer to the equator. This latitude effect has been under investigation for many years. Previous studies have found evidence suggesting that higher lifetime exopsure to sunlight (through which the skin makes vitamin D) and higher blood levels of vitamin D may reduce a person’s risk of developing MS. This is an active area of continued research.

The Ausimmune study was undertaken to investigate whether increased exposure to sunlight in those living closer to the equator and the vitamin D that is produced in part by sunlight may be protective against MS. Rather than studying people who had already been diagnosed with definite MS, which could alter a person’s lifestyle and recollection of past events, the team investigated sun exposure and vitamin D levels in people who had not yet been diagnosed with MS, but who had experienced a CIS. A CIS often, but not always, leads to a diagnosis of MS.

The Study: The investigators recruited participants who were aged 18–59 years and lived in four geographic regions of Australia between November 1, 2003, and December 31, 2006. The four regions were characterized by differing distance from the equator. A total of 216 people were enrolled who had experienced a CIS. A total of 395 controls were randomly selected from the Australian Electoral Roll and matched to the CIS cases in age, gender, and study region.

Sun exposure was measured in several ways, including by participant reports on how much time they spent in the sun during different periods of life starting from age 6, and also by more objective means, such as examination of the skin for sun damage (actinic skin damage) and measurements of skin pigment (melanin). The latitude and longitude of participants’ residence were also recorded as an indicator of ambient ultraviolet (UV) light. Vitamin D levels were measured by a blood sample taken at entry into the study.

The results show that higher recent or lifetime sun exposure and higher blood levels of vitamin D at study entry were independently linked with a reduced risk of CIS. The investigators reported that people with most evidence of skin damage from sun exposure were 60% less likely to develop a CIS than those with the least damage. People with the highest levels of vitamin D at entry also were less likely to have a CIS than those with the lowest levels. As reported in other parts of the world, this study confirmed a latitude effect in Australia. Taken together, differences in sun exposure, vitamin D levels, and skin type accounted for a 32.4% increase in CIS incidence from the low to high latitude regions of Australia.

Comment: This carefully designed and executed study adds important evidence for a protective impact of sun exposure and vitamin D. The authors note that early life sun exposure alone was not associated with CIS risk in this study, and that frequency of ultraviolet light exposure may be more important. They point out that sun exposure and vitamin D levels were independently associated with the risk of developing a CIS, but caution that only a single vitamin D measurement at study entry was available, and that further study is required to determine which of these factors may be more important to this protective effect, and at what stage of a person’s life.

This study does not address the question of whether increasing sun exposure or vitamin D levels through supplements may reduce MS symptoms in people already living with the disease. Also, further research is needed to determine whether safe and effective strategies can be developed that utilize this potential protection without the risks involved in overexposure to the sun or overdoses of vitamin D supplements.

Studies are underway to address those questions. For example, the National MS Society is funding studies of vitamin D, including two clinical trials. Christopher Eckstein, MD (The Johns Hopkins Hospital, Baltimore, MD) and colleagues are testing the impact of different formulas and doses of vitamin D and how it alters the immune system in people who have MS. Ellen Mowry, MD, has just been funded to launch a multi-center, double-blind clinical trial to determine whether high-dose vitamin D added to glatiramer acetate (a standard MS therapy) reduces the frequency of relapses of MS.

“This carefully designed study involving a large collaboration of investigators is exactly the type of research we need to help determine what environmental factors contribute to MS susceptibility,” said Timothy Coetzee, PhD, Chief Research Officer of the National MS Society. “Identifying and understanding risk and triggering factors that cause MS is vital if we’re going to find a way to end MS forever,” he added.

Read more about vitamin D and MS. (link to 12.2.3.7.82_IMSOct06-VitaminD.pdf)


Clinicians who treat people with MS should become familiar with current vitamin D information so that they are able to educate their patients, and, if appropriate, diagnose and treat vitamin D deficiency. Read more (link to ClinBull_Vitamin_D.pdf) in a clinical bulletin for health care professionals about vitamin D and MS.

About Multiple Sclerosis

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share